Last Updated: 09 Nov 2024
Executive Summary
Vivos Therapeutics Inc. (VVOS) is a medical technology company focused on developing and commercializing treatments for sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA). The company has a market capitalization of $13.53 million and is currently trading at $3.09 per share. Analysts have a consensus target price of $7.42, suggesting a potential upside of 140%.
Company Overview
Vivos Therapeutics was founded in 2004 and is headquartered in Highlands Ranch, Colorado. The company's primary product is the Vivos System, a non-surgical treatment for OSA that involves the use of oral appliances to reposition the jaw and improve airway patency. Vivos also offers a range of other products and services related to sleep-disordered breathing, including diagnostic testing, sleep studies, and patient education.
Fundamental Analysis
Vivos Therapeutics has been reporting consistent revenue growth in recent quarters. In the latest quarter (ended June 30, 2024), the company reported revenue of $14.02 million, up 19.4% year-over-year. However, the company continues to operate at a loss, with a net loss of $12.9 million in the latest quarter.
The company's gross profit margin has been improving in recent quarters, reaching 89.9% in the latest quarter. This suggests that Vivos is able to control its costs and maintain profitability as it scales its business.
Vivos Therapeutics has a strong balance sheet with $12.6 million in cash and equivalents as of June 30, 2024. This provides the company with ample liquidity to fund its operations and growth initiatives.
Technical Analysis
The technical analysis of Vivos Therapeutics indicates that the stock is currently in a downtrend. The 50-day moving average is below the 200-day moving average, and the stock price is below both moving averages. This suggests that the stock is likely to continue to decline in the short term.
Short Term Outlook
In the short term, Vivos Therapeutics is likely to continue to face challenges due to its ongoing losses and the competitive nature of the sleep-disordered breathing market. The stock price is likely to remain volatile and could potentially decline further.
Long Term Outlook
In the long term, Vivos Therapeutics has the potential to be a successful company. The company has a strong product portfolio and a growing market opportunity. If the company can continue to execute on its growth strategy and improve its profitability, the stock price could appreciate significantly.
Analyst Recommendations
Analysts have a consensus rating of "Buy" on Vivos Therapeutics. Two analysts have a "Buy" rating, while none have a "Strong Buy," "Hold," "Sell," or "Strong Sell" rating. The average target price is $7.42, suggesting a potential upside of 140%.
